BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS FROM A PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY OF PALIPERIDONE PALMITATE LONG-ACTING INJECTION IN SUBJECTS WITH RECENT-ONSET SCHIZOPHRENIA OR SCHIZOPHRENIFORM DISORDER

被引：0
|
作者：
Brown, Brianne [1 ]
Turkoz, Ibrahim [2 ]
Yue, Yong [1 ]
Alphs, Larry [1 ]
机构：
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Raritan, NJ USA
来源：
SCHIZOPHRENIA BULLETIN | 2017年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
SA.12
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [21] Erratum: Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
    Wolfgang Gaebel
    Andreas Schreiner
    Paul Bergmans
    Rosario de Arce
    Frédéric Rouillon
    Joachim Cordes
    Lars Eriksson
    Enrico Smeraldi
    Neuropsychopharmacology, 2011, 36 : 548 - 548
  • [22] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [23] Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Parellada, Eduard
    Kouniakis, Filippos
    Siurkute, Aldona
    Schreiner, Andreas
    Don, Liana
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (03) : 149 - 154
  • [24] A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior
    Wang, Gang
    Huang, Huiteng
    Wang, Yijun
    Yang, Yongde
    Li, Chang
    Luo, Sen
    Li, Yi
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2024, 129
  • [25] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [26] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, Diego
    Ascher-Svanum, Haya
    Bertsch, Jordan
    Detke, Holland C.
    McDonnell, David
    Maria Haro, Josep
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S357 - S357
  • [27] The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting
    Peitl, Vjekoslav
    Margetic, Branka Aukst
    Vidrih, Branka
    Karlovic, Dalibor
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (01) : 118 - 125
  • [28] Vernakalant hydrochloride injection for the conversion of recent-onset atrial fibrillation to sinus rhythm: summary from 2 randomized, controlled trials and 1 open-label study
    Rasmussen, S. L.
    Englund, A.
    Dickinson, G.
    Kitt, T. M.
    EUROPEAN HEART JOURNAL, 2008, 29 : 286 - 286
  • [29] Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
    McDonnell, David P.
    Landry, John
    Detke, Holland C.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 322 - 331
  • [30] Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
    Alphs, Larry
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Turner, Norris
    ANNALS OF GENERAL PSYCHIATRY, 2011, 10
12345